Cardiac cyclic nucleotide phosphodiesterases: Function, regulation, and therapeutic prospects

Hormone and Metabolic Research

Volumn 44, Issue 10, 2012, Pages 766-775

  Knight, W E ^a   Yan, C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

cAMP; cGMP; heart; PDE

Indexed keywords

AMRINONE; CILOSTAZOL; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DOXORUBICIN; ENOXIMONE; MILRINONE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; PROTEIN KINASE C; SILDENAFIL; TADALAFIL; VALSARTAN; VARDENAFIL; ZAPRINAST;

APOPTOSIS; ARTERY OCCLUSION; CARDIOTOXICITY; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DIASTOLIC HEART FAILURE; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; FIBROBLAST; GENE EXPRESSION; HEART; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYDROLYSIS; IMMUNOHISTOCHEMISTRY; INTERMITTENT CLAUDICATION; LIPOLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; CALCIUM; CARDIOVASCULAR DISEASES; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS;

EID: 84865662834     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0032-1321870     Document Type: Review

References (115)

1. Ding B, Abe J, Wei H, Xu H, Che W, Aizawa T, Liu W, Molina C A, Sadoshima J, Blaxall B C, Berk B C, Yan C. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci USA: 2005; 102 14771 14776
2. Zhang M, Kass D A. Phosphodiesterases and cardiac cGMP: evolving roles and controversies. Trends Pharmacol Sci: 2011; 32 360 365
3. Feldman R D, Gros R. New insights into the regulation of cAMP synthesis beyond GPCR/G protein activation: Implications in cardiovascular regulation. Life Sci: 2007; 81 267 271
4. Chen J, Levin L R, Buck J. Role of Soluble Adenylyl Cyclase in the Heart. Am J Physiol Heart Circul Physiol: 2012; 302 H-538 H-543
5. Iancu R V, Ramamurthy G, Harvey R D. Spatial and temporal aspects of cAMP signalling in cardiac myocytes. Clin Exp Pharmacol Physiol: 2008; 35 1343 1348
6. Halls M L, Cooper DM F. Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, β-arrestin 2, PDE4D3 complex. EMBO J: 2010; 29 2772 2787
7. Zaccolo M. cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br J Pharmacol: 2009; 158 50 60
8. Métrich M, Berthouze M, Morel E, Crozatier B, Gomez A M, Lezoualc'h F. Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology. Pflügers Archiv Eur J Physiol: 2009; 459 535 546
9. Tsai E J, Kass D A. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther: 2009; 122 216 238
10. Castro LR V, Verde I, Cooper D M, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation: 2006; 113 2221 2228
11. Bender A T, Beavo J A. Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use. Pharmacol Rev: 2006; 58 488 520
12. Conti M, Beavo J. Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling. Annu Rev Biochem: 2007; 76 481 511
13. Miller C L, Yan C. Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. J Cardiovasc Transl Res: 2010; 3 507 515
14. Sonnenburg W K, Seger D, Beavo J A. Molecular cloning of a cDNA encoding the "61-kDao" calmodulin-stimulated cyclic nucleotide phosphodiesterase. Tissue-specific expression of structurally related isoforms. J Biol Chem: 1993; 268 645 652
15. Yan C, Zhao A Z, Bentley J K, Beavo J A. The Calmodulin-dependent Phosphodiesterase Gene PDE1C Encodes Several Functionally Different Splice Variants in a Tissue-specific Manner. J Biol Chem: 1996; 271 25699 25706
16. Yan C, Kim D, Aizawa T, Berk B C. Functional Interplay Between Angiotensin II and Nitric Oxide. Arterioscler Thromb Vasc Biol: 2003; 23 26 36
17. Miller C L, Oikawa M, Cai Y, Wojtovich A P, Nagel D J, Xu X, Xu H, Florio V, Rybalkin S D, Beavo J A, Chen Y-F, Li J-D, Blaxall B C, Abe J, Yan C. Role of Ca2+/Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte Hypertrophy. Circ Res: 2009; 105 956 964
18. Nagel D J, Aizawa T, Jeon K-I, Liu W, Mohan A, Wei H, Miano J M, Florio V A, Gao P, Korshunov V A, Berk B C, Yan C. Role of Nuclear Ca2+/Calmodulin- Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival. Circ Res: 2006; 98 777 784
19. Miller C L, Cai Y, Oikawa M, Thomas T, Dostmann W R, Zaccolo M, Fujiwara K, Yan C. Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart. Basic Res Cardiol: 2011; 106 1023 1039
20. Bender A T, Beavo J A. PDE1B2 regulates cGMP and a subset of the phenotypic characteristics acquired upon macrophage differentiation from a monocyte. Proc Natl Acad Sci USA: 2006; 103 460 465
21. Reed T M, Repaske D R, Snyder G L, Greengard P, Vorhees C V. Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning. J Neurosci: 2002; 22 5188 5197
22. Kanda N, Watanabe S. Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. Biochem Pharmacol: 2001; 62 495 507
23. Rybalkin S D, Rybalkina I, Beavo J A, Bornfeldt K E. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res: 2002; 90 151 157
24. Han P, Werber J, Surana M, Fleischer N, Michaeli T. The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion. J Biol Chem: 1999; 274 22337 22344
25. Dunkern T R, Hatzelmann A. Characterization of inhibitors of phosphodiesterase 1C on a human cellular system. FEBS J: 2007; 274 4812 4824
26. Wallis R M, Corbin J D, Francis S H, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol: 1999; 83 3 12
27. Vandeput F, Wolda S L, Krall J, Hambleton R, Uher L, McCaw K N, Radwanski P B, Florio V, Movsesian M A. Cyclic Nucleotide Phosphodiesterase PDE1C1 in Human Cardiac Myocytes. J Biol Chem: 2007; 282 32749 32757
28. Loughney K, Martins T J, Harris EA S, Sadhu K, Hicks J B, Sonnenburg W K, Beavo J A, Ferguson K. Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3,5-Cyclic Nucleotide Phosphodiesterases. J Biol Chem: 1996; 271 796 806
29. Beavo J A, Francis S H, Houslay M D. Cyclic nucleotide phosphodiesterases in health and disease. Boca Raton, Florida CRC Press: 2006
30. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse M J, Pozzan T, Houslay M D, Zaccolo M. Fluorescence Resonance Energy Transfer-Based Analysis of cAMP Dynamics in Live Neonatal Rat Cardiac Myocytes Reveals Distinct Functions of Compartmentalized Phosphodiesterases. Circ Res: 2004; 95 67 75
31. Sun B, Li H, Shakur Y, Hensley J, Hockman S, Kambayashi J, Manganiello V C, Liu Y. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal: 2007; 19 1765 1771
32. Moberg E, Enoksson S, Hagström-Toft E. Importance of phosphodiesterase 3 for the lipolytic response in adipose tissue during insulin-induced hypoglycemia in normal man. Horm Metab Res: 1998; 30 684 688
33. Choi Y H, Ekholm D, Krall J, Ahmad F, Degerman E, Manganiello V C, Movsesian M A. Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem J: 2001; 353 41 50
34. Shakur Y, Holst L S, Landstrom T R, Movsesian M, Degerman E, Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol: 2001; 66 241 277
35. Kostic M M, Erdogan S, Rena G, Borchert G, Hoch B, Bartel S, Scotland G, Huston E, Houslay M D, Krause E-G. Altered Expression of PDE1 and PDE4 Cyclic Nucleotide Phosphodiesterase Isoforms in 7-oxo-prostacyclin-preconditioned Rat Heart. J Mol Cell Cardiol: 1997; 29 3135 3146
36. Mokni W, Keravis T, Etienne-Selloum N, Walter A, Kane M O, Schini-Kerth V B, Lugnier C. Concerted Regulation of cGMP and cAMP Phosphodiesterases in Early Cardiac Hypertrophy Induced by Angiotensin II. PLoS One: 2010; 5 e14227
37. Richter W, Xie M, Scheitrum C, Krall J, Movsesian M A, Conti M. Conserved expression and functions of PDE4 in rodent and human heart. Basic Res Cardiol: 2011; 106 249 262
38. Leroy J, Richter W, Mika D, Castro LR V, Abi-Gerges A, Xie M, Scheitrum C, Lefebvre F, Schittl J, Mateo P, Westenbroek R, Catterall W A, Charpentier F, Conti M, Fischmeister R, Vandecasteele G. Phosphodiesterase 4B in the cardiac L-type Ca2+ channel complex regulates Ca2+ current and protects against ventricular arrhythmias in mice. J Clin Invest: 2011; 121 2651 2661
39. Kotera J, Fujishige K, Imai Y, Kawai E, Michibata H, Akatsuka H, Yanaka N, Omori K. Genomic origin and transcriptional regulation of two variants of cGMP binding cGMP specific phosphodiesterases. Eur J Biochem: 1999; 262 866 873
40. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, Marsboom G, Gheysens O, Vermeersch P, Biesmans L, Liu X, Gillijns H, Pellens M, Van Lommel A, Buys E, Schoonjans L, Vanhaecke J, Verbeken E, Sipido K, Herijgers P, Bloch K D, Janssens S P. Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice. Circulation: 2009; 119 408 416
41. Corbin J, Rannels S, Neal D, Chang P, Grimes K, Beasley A, Francis S. Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr Med Res Opin: 2003; 19 747 752
42. Nagendran J, Archer S L, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka I M, Ross D B, Light P E, Dyck JRB, Michelakis E D. Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility. Circulation: 2007; 116 238 248
43. Kass D A, Takimoto E, Nagayama T, Champion H C. Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res: 2007; 75 303 314
44. Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, Koenke T, O'Rourke B, Champion H C, Crow M T, Kass D A. Expression, Activity, and Pro-Hypertrophic Effects of PDE5A in Cardiac Myocytes. Cell Signal: 2008; 20 2231 2236
45. Lukowski R, Rybalkin S D, Loga F, Leiss V, Beavo J A, Hofmann F. Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. Proc Natl Acad Sci USA: 2010; 107 5646 5651
46. Patrucco E, Albergine M S, Santana L F, Beavo J A. Phosphodiesterase 8A (PDE8A) regulates excitation-contraction coupling in ventricular myocytes. J Mol Cell Cardiol: 2010; 49 330 333
47. Rentero C, Monfort A, Puigdomènech P. Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem Biophys Res Commun: 2003; 301 686 692
48. Galindo-Tovar A, Vargas M L, Kaumann A J. Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of ()-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium. Naunyn-Schmied Arch Pharmacol: 2008; 379 379 384
49. Kaumann A J. Phosphodiesterases reduce spontaneous sinoatrial beating but not the "fight or flighto" tachycardia elicited by agonists through Gs-protein-coupled receptors. Trends Pharmacol Sci: 2011; 32 377 383
50. DiFrancesco D, Tortora P. Direct activation of cardiac pacemaker channels by intracellular cyclic AMP. Nature: 1991; 351 145 147
51. Alig J, Marger L, Mesirca P, Ehmke H, Mangoni M E, Isbrandt D. Control of heart rate by cAMP sensitivity of HCN channels. Proc Natl Acad Sci USA: 2009; 106 12189 12194
52. Galindo Tovar A, Kaumann A J. Phosphodiesterase 4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (-)-adrenaline mediated through mouse cardiac β1adrenoceptors. Br J Pharmacol: 2008; 153 710 720
53. Galindo-Tovar A, Vargas M L, Kaumann A J. Function of cardiac [beta]1- and [beta]2-adrenoceptors of newborn piglets: Role of phosphodiesterases PDE3 and PDE4. Eur J Pharmacol: 2010; 638 99 107
54. Christ T, Galindo-Tovar A, Thoms M, Ravens U, Kaumann A J. Inotropy and L-type Ca2+ current, activated by β1- and β2-adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart. Br J Pharmacol: 2009; 156 62 83
55. Yan C, Miller C L, Abe J. Regulation of Phosphodiesterase 3 and Inducible cAMP Early Repressor in the Heart. Circ Res: 2007; 100 489 501
56. Matthew A M. PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. J Card Fail: 2003; 9 475 480
57. Singh A, Redden J M, Kapiloff M S, Dodge-Kafka K L. The Large Isoforms of A-Kinase Anchoring Protein 18 Mediate the Phosphorylation of Inhibitor-1 by Protein Kinase A and the Inhibition of Protein Phosphatase 1 Activity. Mol Pharmacol: 2011; 79 533 540
58. Layland J, Li J-M, Shah A M. Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes. J Physiol: 2002; 540 457 467
59. Yang L, Liu G, Zakharov S I, Bellinger A M, Mongillo M, Marx S O. Protein kinase G phosphorylates Cav1.2 alpha1c and beta2 subunits. Circ Res: 2007; 101 465 474
60. Dittrich M, Jurevicius J, Georget M, Rochais F, Fleischmann B, Hescheler J, Fischmeister R. Local response of L-type Ca(2+) current to nitric oxide in frog ventricular myocytes. J Physiol (Lond): 2001; 534 109 121
61. Rivet-Bastide M, Vandecasteele G, Hatem S, Verde I, Bénardeau A, Mercadier J J, Fischmeister R. cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest: 1997; 99 2710 2718
62. Méry P F, Lohmann S M, Walter U, Fischmeister R. Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA: 1991; 88 1197 1201
63. Fischmeister R, Castro L, Abi-Gerges A, Rochais F, Vandecasteele G. Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol Part A: Mol Integ Physiol: 2005; 142 136 143
64. Vandecasteele G, Verde I, Rücker-Martin C, Donzeau-Gouge P, Fischmeister R. Cyclic GMP regulation of the L-type Ca2+ channel current in human atrial myocytes. J Physiol: 2001; 533 329 340
65. Mongillo M, Tocchetti C G, Terrin A, Lissandron V, Cheung Y-F, Dostmann W R, Pozzan T, Kass D A, Paolocci N, Houslay M D, Zaccolo M. Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res: 2006; 98 226 234
66. Kerfant B-G, Zhao D, Lorenzen-Schmidt I, Wilson L S, Cai S, Chen SR W, Maurice D H, Backx P H. PI3Kγ Is Required for PDE4, not PDE3, Activity in Subcellular Microdomains Containing the Sarcoplasmic Reticular Calcium ATPase in Cardiomyocytes. Circ Res: 2007; 101 400 408
67. Packer M, Carver J R, Rodeheffer R J, Ivanhoe R J, DiBianco R, Zeldis S M, Hendrix G H, Bommer W J, Elkayam U, Kukin M L. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med: 1991; 325 1468 1475
68. Patrucco E, Notte A, Barberis L, Selvetella G, Maffei A, Brancaccio M, Marengo S, Russo G, Azzolino O, Rybalkin S D, Silengo L, Altruda F, Wetzker R, Wymann M P, Lembo G, Hirsch E. PI3K[gamma] Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects. Cell: 2004; 118 375 387
69. De Arcangelis V, Liu R, Soto D, Xiang Y. Differential association of phosphodiesterase 4D isoforms with beta2-adrenoceptor in cardiac myocytes. J Biol Chem: 2009; 284 33824 33832
70. Baillie G S, Sood A, McPhee I, Gall I, Perry S J, Lefkowitz R J, Houslay M D. beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA: 2003; 100 940 945
71. Richter W, Day P, Agrawal R, Bruss M D, Granier S, Wang Y L, Rasmussen SG F, Horner K, Wang P, Lei T, Patterson A J, Kobilka B, Conti M. Signaling from beta1- and beta2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J: 2008; 27 384 393
72. Lehnart S E, Wehrens XH T, Reiken S, Warrier S, Belevych A E, Harvey R D, Richter W, Jin S-LC, Conti M, Marks A R. Phosphodiesterase 4D Deficiency in the Ryanodine-Receptor Complex Promotes Heart Failure and Arrhythmias. Cell: 2005; 123 25 35
73. Beca S, Helli P B, Simpson J A, Zhao D, Farman G P, Jones P, Tian X, Wilson L S, Ahmad F, Chen SR W, Movsesian M A, Manganiello V, Maurice D H, Conti M, Backx P H. Phosphodiesterase 4D Regulates Baseline Sarcoplasmic Reticulum Ca2+ Release and Cardiac Contractility, Independently of L-Type Ca2+ Current. Circ Res: 2011; 109 1024 1030
74. Takimoto E, Belardi D, Tocchetti C G, Vahebi S, Cormaci G, Ketner E A, Moens A L, Champion H C, Kass D A. Compartmentalization of Cardiac β-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5. Circulation: 2007; 115 2159 2167
75. Borlaug B A, Melenovsky V, Marhin T, Fitzgerald P, Kass D A. Sildenafil Inhibits β-Adrenergic-Stimulated Cardiac Contractility in Humans. Circulation: 2005; 112 2642 2649
76. Takimoto E, Champion H C, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose D C, Isoda T, Aufiero K, Zaccolo M, Dostmann W R, Smith C J, Kass D A. cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism. Circ Res: 2005; 96 100 109
77. Ding B, Abe J, Wei H, Huang Q, Walsh R A, Molina C A, Zhao A, Sadoshima J, Blaxall B C, Berk B C, Yan C. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation: 2005; 111 2469 2476
78. Francis S H, Blount M A, Corbin J D. Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions. Physiol Rev: 2011; 91 651 690
79. Yan C, Ding B, Shishido T, Woo C-H, Itoh S, Jeon K-I, Liu W, Xu H, McClain C, Molina C A, Blaxall B C, Abe J. Activation of Extracellular Signal-Regulated Kinase 5 Reduces Cardiac Apoptosis and Dysfunction via Inhibition of a Phosphodiesterase 3A/Inducible cAMP Early Repressor Feedback Loop. Circ Res: 2007; 100 510 519
80. Abi-Gerges A, Richter W, Lefebvre F, Mateo P, Varin A, Heymes C, Samuel J-L, Lugnier C, Conti M, Fischmeister R, Vandecasteele G. Decreased Expression and Activity of cAMP Phosphodiesterases in Cardiac Hypertrophy and Its Impact on β-Adrenergic cAMP Signals. Circ Res: 2009; 105 784 792
81. Ma D, Fu L, Shen J, Zhou P, Gao Y, Xie R, Li Y, Han Y, Wang Y, Wang F. Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction. Eur J Pharmacol: 2009; 602 348 354
82. Holbrook M, Coker S J. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits. Br J Pharmacol: 1991; 103 1973 1979
83. Marx S O, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks A R. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell: 2000; 101 365 376
84. Wehrens XH T, Lehnart S E, Huang F, Vest J A, Reiken S R, Mohler P J, Sun J, Guatimosim S, Song L-S, Rosemblit N, D'Armiento J M, Napolitano C, Memmi M, Priori S G, Lederer W J, Marks A R. FKBP12.6 Deficiency and Defective Calcium Release Channel (Ryanodine Receptor) Function Linked to Exercise-Induced Sudden Cardiac Death. Cell: 2003; 113 829 840
85. Marx S O, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, Marks A R. PKA Phosphorylation Dissociates FKBP12.6 from the Calcium Release Channel (Ryanodine Receptor): Defective Regulation in Failing Hearts. Cell: 2000; 101 365 376
86. Molina C E, Leroy J, Richter W, Xie M, Scheitrum C, Lee I-O, Maack C, Rucker-Martin C, Donzeau-Gouge P, Verde I, Llach A, Hove-Madsen L, Conti M, Vandecasteele G, Fischmeister R. Cyclic Adenosine Monophosphate Phosphodiesterase Type 4 Protects Against Atrial Arrhythmias. J Am Coll Cardiol: 2012; 59 2182 2190
87. Vandeput F, Krall J, Ockaili R, Salloum F N, Florio V, Corbin J D, Francis S H, Kukreja R C, Movsesian M A. cGMP-Hydrolytic Activity and Its Inhibition by Sildenafil in Normal and Failing Human and Mouse Myocardium. J Pharmacol Exp Therap: 2009; 330 884 891
88. Kukreja R C, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, Xi L. Cardioprotection with phosphodiesterase-5 inhibition - a novel preconditioning strategy. J Mol Cell Cardiol: 2004; 36 165 173
89. Fisher P W, Salloum F, Das A, Hyder H, Kukreja R C. Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity. Circulation: 2005; 111 1601 1610
90. Takimoto E, Champion H C, Li M, Belardi D, Ren S, Rodriguez E R, Bedja D, Gabrielson K L, Wang Y, Kass D A. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med: 2005; 11 214 222
91. Das A, Xi L, Kukreja R C. Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and Apoptosis. J Biol Chem: 2005; 280 12944 12955
92. Koitabashi N, Aiba T, Hesketh G G, Rowell J, Zhang M, Takimoto E, Tomaselli G F, Kass D A. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol: 2010; 48 713 724
93. Redondo J, Bishop J E, Wilkins M R. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase inhibition on collagen synthesis by adult cardiac fibroblasts. Br J Pharmacol: 1998; 124 1455 1462
94. Zhang M, Takimoto E, Hsu S, Lee D I, Nagayama T, Danner T, Koitabashi N, Barth A S, Bedja D, Gabrielson K L, Wang Y, Kass D A. Myocardial Remodeling Is Controlled by Myocyte-Targeted Gene Regulation of Phosphodiesterase Type 5. J Am Coll Cardiol: 2010; 56 2021 2030
95. Das A, Xi L, Kukreja R C. Protein Kinase G-dependent Cardioprotective Mechanism of Phosphodiesterase-5 Inhibition Involves Phosphorylation of ERK and GSK3β J Biol Chem: 2008; 283 29572 29585
96. Takimoto E, Koitabashi N, Hsu S, Ketner E A, Zhang M, Nagayama T, Bedja D, Gabrielson K L, Blanton R, Siderovski D P, Mendelsohn M E, Kass D A. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest: 2009; 119 408 420
97. Chakir K, Zhu W, Tsang S, Woo AY-H, Yang D, Wang X, Zeng X, Rhee M-H, Mende U, Koitabashi N, Takimoto E, Blumer K J, Lakatta E G, Kass D A, Xiao R-P. RGS2 is a primary terminator of [beta]2-adrenergic receptor-mediated Gi signaling. J Mol Cell Cardiol: 2011; 50 1000 1007
98. Frantz S, Klaiber M, Baba H A, Oberwinkler H, Völker K, Ganer B, Bayer B, Abeer M, Schuh K, Feil R, Hofmann F, Kuhn M. Stress-Dependent Dilated Cardiomyopathy in Mice with Cardiomyocyte-Restricted Inactivation of Cyclic GMP-Dependent Protein Kinase I. Eur Heart J Dec: 2011; [Epub ahead of print]. Available from: http://eurheartj.oxfordjournals.org/content/early/2011/12/23/ eurheartj.ehr445
99. Baim D S, McDowell A V, Cherniles J, Monrad E S, Parker J A, Edelson J, Braunwald E, Grossman W. Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N Engl J Med: 1983; 309 748 756
100. Jaski B E, Fifer M A, Wright R F, Braunwald E, Colucci W S. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest: 1985; 75 643 649
101. Amsallem E, Kasparian C, Haddour G, Boissel J-P, Nony P. Phosphodiesterase III inhibitors for heart failure. In: The Cochrane Collaboration Nony P. (ed.). Cochrane Database of Systematic Reviews. Chichester, UK Wiley: 2005
102. Movsesian M A, Alharethi R. Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy. Expert Opin Investig Drugs: 2002; 11 1529 1536
103. Cuffe M S, Califf R M, Adams K F, Benza R, Bourge R, Colucci W S, Massie B M, O'Connor C M, Pina I, Quigg R, Silver M A, Gheorghiade M. Short-Term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure A Randomized Controlled Trial. JAMA: 2002; 287 1541 1547
104. Assad-Kottner C, Chen D, Jahanyar J, Cordova F, Summers N, Loebe M, Merla R, Youker K, Torre-Amione G. The Use of Continuous Milrinone Therapy as Bridge to Transplant Is Safe in Patients With Short Waiting Times. J Card Fail: 2008; 14 839 843
105. Canver C C, Chanda J. Milrinone for long-term pharmacologic support of the status 1 heart transplant candidates. Ann Thor Surg: 2000; 69 1823 1826
106. Chapman T M, Goa K L. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs: 2003; 3 117 138
107. Sun B, Le S N, Lin S, Fong M, Guertin M, Liu Y, Tandon N N, Yoshitake M, Kambayashi J-I. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J Cardiovasc Pharmacol: 2002; 40 577 585
108. Wang S, Cone J, Fong M, Yoshitake M, Kambayashi Ji, Liu Y. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol: 2001; 38 775 783
109. Shakur Y, Fong M, Hensley J, Cone J, Movsesian M A, Kambayashi J-I, Yoshitake M, Liu Y. Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther: 2002; 16 417 427
110. Kass D A, Champion H C, Beavo J A. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res: 2007; 101 1084 1095
111. Bergot E, Magnier R, Zalcman G. Phosphodiesterase Inhibitors for Pulmonary Hypertension. N Eng J Med: 2010; 362 559 560
112. Guazzi M, Vicenzi M, Arena R, Guazzi M D. PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure/Clinical Perspective. Circulation: Heart Fail: 2011; 4 8 17
113. Giannetta E, Isidori A M, Galea N, Carbone I, Mandosi E, Vizza C D, Naro F, Morano S, Fedele F, Lenzi A. Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy: A Randomized, Controlled Clinical Trial Using Magnetic Resonance Imaging with Myocardial Tagging. Circulation: 2012; 125 2323 2333
114. Herrmann H C, Chang G, Klugherz B D, Mahoney P D. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med: 2000; 342 1622 1626
115. Denardo S J, Wen X, Handberg E M, Bairey Merz C N, Sopko G S, Cooper-Dehoff R M, Pepine C J. Effect of Phosphodiesterase Type 5 Inhibition on Microvascular Coronary Dysfunction in Women: A Women's Ischemia Syndrome Evaluation (WISE) Ancillary Study. Clin Cardiol: 2011; 34 483 487